Introduction
Notch signaling is an evolutionarily conserved pathway which regulates critical cellular pathways and plays a key role in the development of normal tissues and cells through various effects on differentiation, proliferation, cell fate decision, and stem cell renewal (1) (2) (3) . The Notch signaling pathway includes Notch receptors, ligands, negative and positive modifiers, and Notch target transcription factors. To date, 4 Notch receptors have been identified in mammals (i.e., Notch1, Notch2, Notch3, and Notch4). Five types of Notch-binding ligands have been identified, namely, delta-like-1, delta-lik-3, deltalike-4, Jagged-1, and Jagged-2 (4, 5) . The receptors of the Notch family are large transmembrane epidermal growth factor-like repeat-containing proteins, whereas the ligands are also transmembrane proteins containing multiple epidermal growth factor-like repeats and can activate Notch receptors in most contexts (6, 7) . After ligand binding, Notch receptors undergo a series of modifications, including a proteolytic cleavage operated by a g-secretase complex that releases the intracellular domain of Notch receptors (Notch IC , active form of Notch). Then, Notch IC translocates to the nucleus and interacts with Cpromoter-binding factor 1 (CBF-1) transcription factors, which is also known as RBP-Jk. Interaction of Notch IC with CBF-1 promotes the release of transcriptional corepressors and recruits transcriptional coactivators to the CBF-1 complex, which modulates Notch-mediated transcription and promotes feedback inhibition of Notch pathway signaling (8, 9) .
Aberrantly activated Notch signaling has been shown to play a key role in carcinogenesis and progression of human malignancy (10) . Notch signaling is reported to be aberrantly activated and plays an oncogenic role in a variety of human cancers such as T-cell acute lymphoblastic leukemia, lung, prostate, and breast carcinomas (11) (12) (13) (14) . In contrast to its tumor oncogenic role, Notch signaling has a tumor-suppressive effect on murine skin tumors, B-cell malignancies, neural crest tumors, and in small-cell lung cancer (15) (16) (17) . Considering the tissuespecific role of Notch signaling, it is necessary to investigate the role of Notch1 in human colorectal cancer to further understand the function of Notch signaling. In our previous study, we provided the first evidence that Notch1 expression was upregulated and associated with tumor differentiation status in colorectal cancer, whereas Notch2 expression was decreased and inversely correlated with differentiation status (18, 19) . Moreover, we have also showed that Notch1 level was associated with overall survival of patients with colorectal cancer (20, 21) . However, the canonical Notch pathway that has been well characterized is relatively simple compared with its various functions in tumorigenesis/carcinogenesis and progression. Recently published data suggest that noncanonical Notch signaling mechanisms could be an explanation for the Notch puzzle, among which nuclear factor kB (NF-kB) pathway could be the most important one for NF-kB transcription factors control the expression of a multitude of genes with multiple functions in cancer. While the manner in which Notch signaling cross-talks with other, pathways appears to be extraordinarily complex and, not surprisingly, context dependent. Till now, the prognostic value of Notch1 as well as its relationship with p65 in colorectal cancer has not been described.
In the present study, we investigated the prognostic value of Notch1, as well as its association with p65, in a retrospective study cohort and a prospective study cohort with large sample size and long follow-up to determine the independent predictive role of Notch1 in patients with colorectal cancer and the potential mechanism that Notch1 modulates human cancer progression.
Materials and Methods

Study cohort and tissue samples
This study was approved by the Ethics Committee of the Fourth Military Medical University and Tianjin Union Medicine Centre. All patients from the 2 separate centers provided full consent for the study. The study population involved a retrospective study cohort as exploratory data set and a prospective cohort as validation data set. The retrospective cohort, including 681 patients with potentially resectable colorectal cancer diagnosed from January 2003 to December 2006, was from Colorectal Cancer Registry, Tianjin Union Medicine Centre. Patients with following criteria were excluded: received treatment prior to surgery including neoadjuvant chemotherapy; harvested insufficient specimens for tissue microarray preparation; diagnosed as gastrointestinal stromal tumor or lymphoma; diagnosed with additional cancers; and refused consent. All the clinical specimens were retrieved from the tissue archive of the Department of Pathology, Tianjin Union Medicine Centre and uniquely identified by laboratory numbers that allowed cross-referencing with clinical data from the tumor registry without disclosure of patient identity. Follow-up information of all participants was updated every 3 months by telephone and questionnaire letters.
The prospective cohort recruited 260 patients consecutively diagnosed as colorectal cancer from January 2004 to December 2005 in Department of Gastrointestinal Surgery, Xijing Hospital, the Fourth Military Medical University. The exclusion criteria for recruitment were the same as the retrospective cohort. Patients' clinicopathologic information and follow-up data of the remaining 260 patients were prospectively entered into a database, which was under a close follow-up scheme and updated with respect to survival status every 3 months. All the specimens had been histologically diagnosed by Department of Pathology, Xijing Hospital, the Fourth Military Medical University. Overall survival is defined as the time elapsed from surgery to death of patients. Death of participants was ascertained by reporting from the family and verified by review of public records. We also collected histologically normal biopsy tissues from patients who underwent endoscopy during 1998-2000 and did not develop colorectal cancer within 10 years as internal controls. For both study cohorts, patients with colorectal cancer of stages I, II, and III had all been under radical surgery, whereas patients with stage IV colorectal cancer had all been under surgery for potential cure (i.e., liver metastases). All the fresh tissues were obtained within 10 minutes after surgical removal, then fixed in 10% formaldehyde, and embedded in paraffin for histologic sections. Study physicians who reviewed all the records of colorectal cancer and recorded data into database were totally blind to exposure data.
Tissue microarray preparation and immunohistochemistry
Sixteen array blocks containing all cases from the 2 study cohorts were prepared, as described previously (22) (23) (24) .
Translational Relevance
The predictive role of Notch1 on prognosis of colorectal cancer and the relation between Notch1 and p65 have not been investigated. In this study, we utilized a large sample of clinical specimens (n ¼ 941) and tissue microarray methods to evaluate Notch1 and p65 expression in 2 separate cohorts including a retrospective and a prospective study cohort. To our knowledge, this is the first prospective research that proved the prognostic predictive roles of Notch1 in colorectal cancer, which could be modified by p65. Therefore, Notch1 together with p65 could be a more efficient prognosis predictor and therapeutic target for colorectal cancer considering their integral function. Moreover, our study suggested a novel possible mechanism for Notch1 to modulate human carcinogenesis through nuclear factor kB (NF-kB) signaling by regulating p65. These data indicated a potential role of Notch1 as prognostic predictor and therapeutic target, both of which are relevant to practice in clinical oncology.
Briefly, for tissue microarray construction, a hematoxylin and eosin (H&E)-stained section was made from each block and then reviewed by 1 pathologist to define representative tumor regions. Core biopsy specimens of 1 mm in diameter were taken from carefully selected, morphologically representative regions of individual paraffinembedded donor blocks and arrayed into a recipient paraffin block (45 Â 20 mm 2 ), using a tissue puncher/ arrayer (Beecher Instruments). A second core was arrayed for each specimen, representing 2-fold redundancy for each case. Each block contained 10 internal controls consisting of nonneoplastic colorectal mucosa. After construction, 4-mm sections were cut from each block and stained with H&E on the initial slides. The quality of morphologic preservation in the tissue microarray section was assessed against the whole tissue sections of the same case. A valid case was defined as a tumor occupying more than 10% of the core area (25) . Four-mm sections of the resulting multitumor tissue array blocks were then transferred to glass slides for immunohistochemical staining.
Immunohistochemistry was conducted using the avidin-biotin-peroxidase method on all the16 colorectal cancer tissue microarrays. All sections were deparaffinized in xylene and dehydrated through a gradient concentration of alcohol before endogenous peroxidase activity was blocked with 0.5% H 2 O 2 in methanol for 10 minutes. After nonspecific binding was blocked, slides were incubated with antibodies of activated Notch1 (1:100; Abcam; ab8387) or p65 (1:100; Abcam; ab7970) in PBS at 4 C overnight in a moist box (26) . Biotinylated goat anti-rabbit IgG (1:800; Sigma; B8895) was incubated with the sections for 1 hour at room temperature and detected with a streptavidin-peroxidase complex. The brown color indicative of peroxidase activity was developed by incubating with 0.1% 3,3 0 -diaminobenzidine (Sigma) in PBS with 0.05% H 2 O 2 for 5 minutes at room temperature. Negative controls were conducted by replacing the primary antibody with preimmune rabbit serum. Positive controls were conducted as suggested by the manufacturer. Negative and positive controls were conducted in each run of immunohistochemistry.
Evaluation of staining
Multiple tissue arrays were scored independently by 2 pathologists blinded to the clinicopathologic characteristics and outcome of the patients. The quality of immunohistochemical staining (intensity and appropriate cellular localization of reaction) was also assessed and compared to verify the quality and representativeness of the tissue microarrays. The staining was evaluated by scanning the entire tissue specimen under low magnification (Â40) and then confirmed under high magnification (Â200 and Â400). An immunoreactivity score system based on the proportion and intensity of positively stained cancer cells was applied (27) . The extensional standards taken were as follows: (i) number of positive stained cell 5%, scored 0; 6%-25%, scored 1; 26%-50%, scored 2; 51%-75%, scored 3; and >75%, scored 4 and (ii) intensity of stain: colorless, scored 0; pallideflavens, scored 1; yellow, scored 2; and brown scored 3. The extensional standards (i) and (ii) were multiplied and the staining grade was stratified as absent (0 score), weak (1-4 score), moderate (5-8 score), and strong (9-12 score). All stained slides were interpreted by another pathologist unaware of other data. Specimens will be rescored if difference of scores from 2 pathologists was more than 3. The concordance of Notch1 scoring between the 2 observers was 0.91 (j ¼ 0.62; P < 0.001) and that of p65 was 0.93 (j ¼ 0.64; P < 0.001), indicating substantial agreement. Tumors with moderate or strong immunostaining were classified as having positive (þ) expression, whereas tumors with absent or weak immunostaining were classified as having negative (À) expression.
Statistical analysis
Statistical analysis was undertaken by SPSS statistical software (version 11.0). Spearman's rank test was used to assess the correlation between Notch1 and p65 expressions. Survival curves were estimated using the KaplanMeier method, and differences in survival distributions were evaluated by the log-rank test. Cox's proportional hazards modeling of factors potentially related to survival was conducted to calculate HRs and identify which factors might have a significant influence on survival. Age of diagnosis was used as continuous variables when adjusting for potential confounding, whereas other covariates were used as categorical variables. Differences with a value of P 0.05 were considered to be statistically significant and all P values were determined from 2-sided tests.
Results
Colorectal cancer tissue array analysis
The clinicopathologic characteristics of the retrospective and prospective cohorts are shown in Table 1 . Among the 681 tumors in retrospective cohort, 407 (59.8%) were positive for Notch1 expression, whereas 274 (40.2%) were negative for Notch1 expression. While among the 260 tumors in prospective cohort, 138 (53.1%) were positive for Notch1 expression, whereas 122 (46.9%) were negative for Notch1 expression. As the relationship between Notch1 expression and clinical features of colorectal cancer had been described in our early publication, we did not show it here (18, 19) . We have also examined p65 status by immunohistochemistry simultaneously. In retrospective cohort, 363 (53.3%) were positive for p65 expression and 318 (46.7%) were negative for p65 expression. While in prospective cohort, 127 (48.8%) were positive for p65 expression and 133 (51.2%) were negative for p65 expression. The staining patterns of Notch1 and p65 were shown in Supplementary Figures. There was a significant positive correlation between Notch1 and p65 expression in both retrospective (r ¼ 0.144, P < 0.001) and prospective study cohorts (r ¼ 0.210, P ¼ 0.001), indicating the potential interaction of the 2 protein.
Exploratory data set
We recruited 681 patients in the retrospective study. Among these eligible patients, the actual overall median survival time was 54 months (range: 1-76 months). Among the 681 patients, 304 (44.6%) patients were alive and 377 (55.4%) were dead at the time of analysis.
The protein expression of Notch1 in colorectal cancer was investigated for associations with overall survival using Kaplan-Meier analysis and log-rank test for significance estimates. Patients were divided into 2 groups those with positive expression and those with negative expression, as described in the evaluation of staining. A statistically significant difference of overall survival was found between colorectal cancer patients with tumors having positive Notch1 expression and tumors with negative Notch1 expression. Kaplan-Meier survival curves showed that higher Notch1 expression was associated with worse overall survival (log-rank test: P < 0.001; Fig. 1A) . The median survival time of patients with positive expression of Notch1 was 54 months, whereas that of patients with negative expression of Notch1 could not be estimated because of long survival time. Patients with higher expression levels of Notch1 tended to have higher risk of death than patients with lower expression of Notch1, with the unadjusted HR being 1.92 (95% CI: 1.08-4.19; P < 0.001). In addition, differentiation status, lymph node metastasis, and TNM stage proved to be associated with prognosis of patients with colorectal cancer. Patients with tumors of poor differentiation, lymph node metastasis, or advanced TNM stage had shorter survival and higher risk of death than those without. However, sex, age, tumor location, or tumor size had no prognostic value for survival of patients. Unadjusted HR was shown in Table 2 .
In multivariate analysis, Cox proportional hazards model was adjusted for gender, age, tumor size, tumor location, differentiation status, vascular invasion, and TNM stage. As a result, higher Notch1 expression was associated with a significant decrease of overall survival of patients, with the adjusted HR being 2.31 (95% CI: 1.24-4.95; P < 0.001), indicating that Notch1 expression could be a prognostic factor independent of these adjusted clinicopathologic characteristics ( Table 2) .
As statistical results of staining revealed a significant positive correlation between Notch1 and p65 expression, we set out to detect whether the impact of Notch1 on prognosis of colorectal cancer patients was influenced by p65 status. Patients were subsequently divided into 4 groups according to combined expression levels of Notch1 and p65. Kaplan-Meier analysis showed statistically distinct survival patterns among the 4 subgroups (Fig. 1B) . In both positive Notch1 and negative Notch1 tumors, patients with tumors of negative p65 expression had a better survival compared with patients with tumors of positive p65 expression (Fig. 1C and D) whereas the survival of patients with colorectal cancer of aberrant coexpression of Notch1 and p65 was not statistically different (Fig. 1E) . In multivariate analysis adjusted for gender, age, tumor size, tumor location, differentiation status, vascular invasion, and TNM stage, compared with tumors with negative coexpression of Notch1 and p65, positive coexpression of Notch1 and p65 was associated with poor survival, revealing that the predictive role of Notch1 on clinical outcome was modified by p65 status (Table 3) . Validation data set A total of 260 patients with colorectal cancer were recruited in the prospective study cohort. The data set was similar to the retrospective cohort about clinicopathologic characteristics. The median follow-up time was 55 months (range: 1-84 months). The mean overall survival time of all the 260 eligible patients with colorectal cancer was 61.8 AE 1.6 months. Protein expression levels were comparable in both study cohorts for Notch1 (positive: 59.8% vs. 53.1%) and p65 (positive: 53.3% vs. 48.8%). Among the 260 patients in prospective cohort, 119 (45.8%) patients were alive and 141 (54.2%) were dead at the time of analysis, compared with 304 (44.6%) and 377 (55.4%), respectively, in the retrospective cohort.
The association between Notch1 level and survival of patients was explored by Kaplan-Meier analysis and log-rank test as conducted in retrospective study cohort. Kaplan-Meier overall survival curves showed a significant association between short survival and positive expression of Notch1 ( Fig. 2A) , with the unadjusted HR being 2.26 (95% CI: 1.18-4.85; P < 0.001). Differentiation status, lymph node metastasis, and TNM stage also proved to be associated with prognosis of patients with colorectal cancer. However, gender, age, tumor location, tumor size, or vascular invasion had no prognostic value. Unadjusted HR was shown in Table 4 . We further conducted a Cox regression analysis to assess whether Notch1 was a prognostic predictor of survival independent of gender, age, tumor size, tumor location, differentiation status, vascular invasion, and TNM stage.
Results showed that Notch1 was a significant independent predictor of survival for patients with colorectal cancer. The adjusted HR for patients with negative Notch1 expression tumor was 2.51 (95% CI: 1.28-5.73; P < 0.001). The results of univariate and multivariate analysis in prospective study cohort were consistent with that in retrospective study cohort (Table 4) .
Because the results in retrospective study cohort showed the prognostic value of Notch1 was modified by p65 status. We therefore divided patients by combined Notch1 and p65 status to test the accordance in prospective cohort. Kaplan-Meier analysis showed that survival patterns of the 4 subgroups were statistically different, among which patients with positive coexpression of Notch 1 and p65 endured the worst overall survival (Fig. 2B ). In addition, negative p65 level was associated with long overall survival in both positive and negative Notch1 patients ( Fig. 2C and D), whereas no difference of survival between patients with aberrant coexpression of the 2 proteins was detected (Fig. 2E) . In Cox proportional hazards model adjusted for gender, age, tumor size, tumor location, differentiation status, vascular invasion, and TNM stage, compared with tumors with negative coexpression of Notch1 and p65, positive coexpression of Notch1 and p65 was associated with a significant poor survival. However, among patients with positive Notch1 tumors, high p65 expression was associated with poor overall survival. The same trend was observed among patients with negative Notch1 tumors ( Table 4 ), indicating that Notch1 was an independent prognostic predictor which could be modified by p65 status for the combination of positive expression of Notch1 and p65 that defined a subgroup of patients with extremely poor outcome. These results were consistent with that of the retrospective cohort.
Discussion
Colorectal cancer is one of the most common malignant tumors worldwide (28, 29) . In China alone, there were more than 340,000 new cases diagnosed per year, leading to over 80,000 deaths every year, ranking colorectal cancer fifth of all cancer-related deaths. Despite earlier diagnosis, advances in radical surgery, radiotherapy, and neoadjuvant chemotherapy, many colorectal cancers remain incurable (30) . In the last decades, the incidence of colorectal cancer has been increasing (31) . One of the greatest challenges in colorectal cancer management now is to accurately predict outcome for each patient so that we can determine who will benefit from adjuvant therapy. To achieve this, presently people rely heavily on traditional pathologic variables. However, clinical staging systems often fail to discriminate the biological nature of a large number of tumors. Currently, TNM and Dukes' staging system of tumors is the gold standard for determining prognosis in patients with colorectal cancer. Whereas the TNM staging system relied on the extent of disease at time of diagnosis is highly predictive of outcome at the extremes (e.g., prognosis of stage I vs. stage IV tumors), it is less informative for intermediate groups and each patient. Patients with similar stages of disease even showed a big discrepancy in survival. Molecules involved in cancer prognosis might serve as markers for early detection of metastasis and as measurement for therapeutic intervention (32) (33) (34) (35) (36) .
Notch signaling pathway regulates a wide variety of cellular processes during development and plays a crucial role in human malignant diseases. Although the intracellular transduction of the Notch signal is remarkably simple, with no secondary messengers, this pathway functions in an enormous diversity of developmental processes and its dysfunction is implicated in many cancers. It regulates a number of cellular properties important in cancer including cell division, differentiation, and survival (10) . So far, the role of Notch1 in cancer remains controversial and cell context-dependent, and high level of Notch1 prevents normal differentiation, leading to malignancy and transformation, highly denoting an oncogenic role of Notch1 in various cancers (11) (12) (13) (14) . However, the potential mechanism for the oncogenic role of Notch 1 in colorectal cancer remains unclear. The canonical ligand-binding Notch pathway is comparatively simple and involves a limited number of obligatory components (37) . Recently, several reports showed that Notch signaling could cross-talk with multiple other pathways in T-cell acute lymphoblastic leukemia (37, 38) . Among the most intricate cross-talks described for Notch is its interaction with the NF-kB pathway, another major cell fate regulatory network involved in development, immunity, and cancer, which is an important regulator of cell survival, cell cycle, cell adhesion, and migration (38) . As these processes, when deregulated, are the hallmarks of tumor induction, the NF-kB pathway has been implicated in a variety of human cancers (39, 40) . However, the possible relationship between Notch signaling and NF-kB pathway has not been reported yet. We conducted the present study to detect the relation of Notch1 protein expression with clinical outcome of colorectal cancer patients, as well as the association between Notch1 and p65. Our present study involved a large number of colorectal cancer specimen in 2 separate study cohorts, 681 for retrospective cohort and 260 for prospective cohort, with adequate follow-up time as well as intimate information on clinicopathologic characteristics. This comprehensive study allowed us to evaluate the predictive value of Notch1 on prognosis of patients with colorectal cancer more efficiently. Traditionally, protein levels were used for diagnosis and prognosis because mRNA amount is not always correlated with protein level. However, scoring of staining is a problem for any immunohistochemistrybased detection. Here, we utilized an immunoreactivity score system with all the cores on the slides viewed by 2 separate pathologists under double-blind condition, with rigorous comparison with internal controls. And our previous study has shown that Western blot results correlated well with immunohistochemical expression of Notch1 (18) . Thus, we would have been able to detect the predictive effect of Notch1 on patients' survival independent of clinical factors as well as its relation to p65 effectually and efficiently.
Our current study has comprehensively evaluated the protein expression of Notch1 and p65, as well as the association with patients' survival. The results clearly showed that protein expression of Notch1 is a prognostic predictor for overall survival in patients with colorectal cancer, independent of gender, age, tumor size, tumor location, differentiation status, vascular invasion, and TNM stage. And the protein expression of Notch1 positively correlated with that of p65 in clinical colorectal specimens. Furthermore, the predictive role of Notch1 for prognosis might be modified by p65 status. The results provided the first evidence for Notch1 to determine the prognosis of patients with colorectal cancer and positively correlated with p65. It could contribute to accurate prediction of the prognosis of patients following surgery and consequently to make tailored treatment of each patient, thus preventing patients from receiving excessive or insufficient adjuvant treatment, both of which were harmful. The possible mechanism which underlies the predictive role of Notch1 might be its interaction with NF-kB activity. We found a significant positive association between Notch1 and p65 protein expression that tumors with positive Notch1 expression are more likely to be positive for p65 expression, which support the notion that Notch1 could stimulate NF-kB activity through a transcriptional upregulation of p65. While no difference of survival was found between patients with aberrant coexpression of Notch1 and p65, indicating that efficacy of either Notch1 or p65 is lost in the pathway, which might lead to attenuation of colorectal carcinogenesis and progression. Thus, the integral function of Notch1 and p65 plays a key role in human colorectal carcinogenesis and progression.
However, the complexity of the NF-kB pathway makes it likely that there are numerous regulated gene products (41) (42) (43) . It is unlikely that Notch1 is the only molecule which could stimulate NF-kB activity. So, the effect of Notch1 on p65, the mechanism of transcriptional activation of Notch1 on p65, as well as the other possible mechanism for Notch1 to stimulate NF-kB pathway are to be further studied in future research.
In conclusion, to our knowledge, this is the first study to describe the relation between Notch1 and p65 as well as the predictive role of Notch1 in colorectal cancer. Our retrospective and prospective study provided convincing evidence that Notch1 could be an independent predictor of prognosis for patients with colorectal cancer, which might be modified by p65 status. It also suggested a possible mechanism for Notch1 to modulate human carcinogenesis and progression through activation of NF-kB signaling by stimulating p65. Therefore, targeting Notch1 and p65 could be a promising therapeutic strategy for future therapies of colorectal cancer.
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